OncoImmuno
New York, United States· Est.
Developing next-generation, multi-specific antibody therapies for cancer and immune disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $580M
AI Company Overview
Developing next-generation, multi-specific antibody therapies for cancer and immune disorders.
OncologyImmunology
Technology Platform
A proprietary antibody engineering platform for the rapid development of multi-specific antibodies with tailored immune-modulating functions.
Funding History
1Total raised:$580M
Follow-on Offering$580M
Opportunities
Potential to address oncology and immunology indications where current checkpoint inhibitors and biologics have limited efficacy.
Risk Factors
High technical and clinical risk associated with novel antibody formats and potential for immune-related adverse events.
Competitive Landscape
Operates in the crowded bispecific antibody field, competing with large pharma and biotechs like Genmab and Zymeworks.